|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93.53 USD | -0.81% |
|
-0.42% | -1.75% |
| 07-08 | Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says | MT |
| 07-08 | Morgan Stanley Adjusts Price Target BioNTech to $119 From $126, Maintains Overweight Rating | MT |
Company Valuation: BioNTech SE
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 54,749 | 34,159 | 22,698 | 26,387 | 19,497 | 20,745 | - | - |
| Change | - | -37.61% | -33.55% | 16.25% | -26.11% | 6.41% | - | - |
| Enterprise Value (EV) 1 | 53,358 | 20,496 | 11,253 | 16,879 | 12,356 | 9,891 | 11,460 | 10,683 |
| Change | - | -61.59% | -45.1% | 50% | -26.8% | -19.95% | 15.86% | -6.78% |
| P/E | 5.72x | 3.72x | 24.9x | -39.7x | -17.3x | -18.7x | -18.4x | -20.5x |
| PBR | 4.62x | 1.7x | 1.12x | - | 1.06x | 1.15x | 1.27x | 1.36x |
| PEG | - | -0.79x | -0.3x | 0x | -0.2x | 2.9x | -11.22x | 1.9x |
| Capitalization / Revenue | 2.89x | 1.97x | 5.94x | 9.59x | 6.79x | 9.57x | 9.3x | 8.28x |
| EV / Revenue | 2.81x | 1.18x | 2.95x | 6.14x | 4.31x | 4.56x | 5.14x | 4.26x |
| EV / EBITDA | 3.47x | 1.61x | 12.9x | -16.6x | -12.1x | -7.99x | -8.89x | -10.6x |
| EV / EBIT | 3.49x | 1.62x | 16.3x | -12.8x | -8.79x | -6.56x | -7.51x | -8.44x |
| EV / FCF | 72.5x | 1.55x | 2.41x | -69x | 44x | -6.36x | -9.17x | -13.3x |
| FCF Yield | 1.38% | 64.5% | 41.5% | -1.45% | 2.27% | -15.7% | -10.9% | -7.54% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 39.63 | 37.77 | 3.83 | -2.77 | -4.7 | -4.397 | -4.469 | -3.996 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18,977 | 17,311 | 3,819 | 2,751 | 2,870 | 2,168 | 2,231 | 2,505 |
| EBITDA 1 | 15,359 | 12,766 | 873.8 | -1,016 | -1,022 | -1,237 | -1,288 | -1,004 |
| EBIT 1 | 15,284 | 12,643 | 690.4 | -1,314 | -1,405 | -1,509 | -1,525 | -1,266 |
| Net income 1 | 10,292 | 9,434 | 930.3 | -665.3 | -1,136 | -1,049 | -1,165 | -977.6 |
| Net Debt 1 | -1,391 | -13,663 | -11,445 | -9,508 | -7,141 | -10,854 | -9,286 | -10,063 |
| Reference price 2 | 226.68 | 140.56 | 95.48 | 110.06 | 81.08 | 82.04 | 82.04 | 82.04 |
| Nbr of stocks (in thousands) | 241,521 | 243,019 | 237,716 | 239,740 | 240,455 | 252,884 | - | - |
| Announcement Date | 3/30/22 | 3/27/23 | 3/20/24 | 3/10/25 | 3/10/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -18.66x | 4.56x | -7.99x | -.--% | 23.65B | |
| 34.48x | 8.66x | 26.88x | 0.05% | 56.71B | |
| 19.3x | 5.92x | 12.91x | 1.56% | 51.3B | |
| -44.07x | 14.64x | -42.66x | -.--% | 25.26B | |
| 23.4x | 4.6x | 12.02x | -.--% | 18.69B | |
| 24.3x | 4.84x | 15.77x | -.--% | 17.71B | |
| 52.96x | 24.1x | 62.06x | 0.07% | 17.7B | |
| -500.51x | 34.41x | -3836.85x | -.--% | 14.26B | |
| 17.65x | 5.13x | 11.97x | -.--% | 14.1B | |
| -81.09x | 8.36x | -74.99x | -.--% | 13.04B | |
| Average | -47.22x | 11.52x | -382.09x | 0.17% | 25.24B | |
| Weighted average by Cap. | -18.81x | 10.08x | -209.96x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BNTX Stock
- Valuation BioNTech SE
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
